Molecular and cellular analysis of the ABHD5/PNPLA3 metabolon in lipid homeostasis

ABHD5/PNPLA3 代谢在脂质稳态中的分子和细胞分析

基本信息

批准号：
10453590
负责人：
Emilio Mottillo
金额：
$ 47.62万
依托单位：
WAYNE STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-19 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10453590
关键词：
Acyl Coenzyme A Address Adipocytes Adipose tissue Affinity Animal Model Binding Binding Sites Biological Assay Cell physiology Cells Chemicals Complex Coupled Data Diabetes Mellitus Disease Disease Progression Enzymes Equilibrium Esterification Family member Fatty Acids Fatty acid glycerol esters Fluorescence Foundations Genetic Genetic Models Goals Health Hepatocyte Homeostasis Human Hydrolase Imaging Techniques Immunoprecipitation Insulin Resistance Isotopes Knock-out Label Ligands Lipase Lipids Lipolysis Liver Location Malignant Neoplasms Maps Metabolic Metabolism Mission Modeling Molecular Monitor Muscle Nature Obesity Obesity associated disease Organelles Pathologic Pathway interactions Pharmacology Phospholipase Physiological Play Primary carcinoma of the liver cells Process Proteins Proteomics Publishing Regulation Resolution Risk Factors Role Surface Techniques Therapeutic Intervention Tissues Tracer Transmission Electron Microscopy Triglycerides United States National Institutes of Health Variant Very low density lipoprotein Work cell type fatty liver disease gain of function genetic risk factor genetic variant high resolution imaging improved lipid metabolism lipidomics loss of function molecular imaging mutant novel novel therapeutics obesity treatment protein complex protein protein interaction response tool trafficking

项目摘要

Project Summary/Abstract The balance between triacylglycerol (TAG) storage and mobilization in adipose tissue and liver is critical to metabolic health as the dysregulation during obesity can produce ectopic accumulation of lipids in muscle and liver, resulting in the progression to diabetes and fatty liver disease (FLD). Thus, an important long-term scientific goal is to understand the tissue-specific molecular mechanisms that control TAG metabolism in order to discover novel therapies. Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) is a protein that is highly expressed in lipogenic tissues, like fat and liver, and is highly upregulated under conditions that promote fat storage. Importantly, a common genetic variant of PNPLA3, I148M, is the greatest known risk factor for developing FLD and its pathological sequelae. In recently published and preliminary data, we demonstrate that α/β hydrolase domain containing protein 5 (ABHD5), an enzyme co-activator, strongly interacts with PNPLA3 and the disease-causing I148M variant is a gain-of-function. Furthermore, the interaction between PNPLA3 I148M and ABHD5 is particularly effective in promoting cellular TAG retention, which likely plays a central role in disease progression. Importantly, the ABHD5/PNPLA3 interaction can be dynamically regulated by endogenous fatty acids and synthetic ABHD5 ligands. This work will examine the basic mechanism of how ABHD5 regulates the function of PNPLA3 and the I148M variant in adipocytes and hepatocytes using high resolution imaging techniques, proximity proteomics and metabolic tracers/lipidomics in conjunction with robust genetic models and an integrative panel of endogenous fatty acid ligands and chemical probes. Our Specific Aims are: 1) To determine the molecular basis for the interaction of ABHD5 with WT PNPLA3 and I148M and the subcellular location and dynamic trafficking of ABHD5 complexes in adipocytes and hepatocytes using high resolution fluorescence and transmission electron microscopy. 2) To determine the location and ligand-dependent protein composition of the ABHD5/PNPLA3 and ABHD5/ PNPLA3 I148M metabolons using nonbiased proximity proteomics and directed immunoprecipitation. 3) To dissect the metabolic function of the ABHD5/PNPLA3 and ABHD5/PNPLA3 I148M metabolons in adipocytes and hepatocytes using gain- and loss- of-function genetics and selective endogenous and synthetic ABHD5 ligands in conjunction with isotope tracers and lipidomics. These goals, which are well aligned with the mission of the NIH will be implemented within a discovery platform that maximizes integration across level of analysis (molecular, organelle, cells and tissues) to provide a robust analysis of ABHD5/PNPLA3 function, thereby improving our understanding of how lipids levels are regulated and identify novel points for therapeutic intervention in obesity related disorders.

项目概要/摘要脂肪组织和肝脏中三酰甘油 (TAG) 储存和动员之间的平衡对于代谢健康至关重要，因为肥胖期间的失调会导致肌肉和肝脏中脂质异位积累，从而导致糖尿病和脂肪肝疾病 (FLD) 的进展。因此，一个重要的长期科学目标是了解控制 TAG 代谢的组织特异性分子机制，以发现含有 3 的 Patatin 样磷脂酶结构域的新疗法。 (PNPLA3) 是一种在脂肪和肝脏等脂肪生成组织中高度表达的蛋白质，并且在促进脂肪储存的条件下高度上调。重要的是，PNPLA3 的常见遗传变异 I148M 是发生 FLD 的最大已知风险因素。及其病理后遗症在最近发表的初步数据中，我们证明α/β强水解酶结构域含有蛋白5（ABHD5），一种酶共激活剂，与PNPLA3和PNPLA3相互作用。此外，PNPLA3 I148M 和 ABHD5 之间的相互作用在促进细胞 TAG 保留方面特别有效，这可能在疾病进展中发挥核心作用。受内源性脂肪酸和合成 ABHD5 配体动态调节本工作将研究 ABHD5 如何调节 PNPLA3 和 I148M 变体的功能的基本机制。使用高分辨率成像技术、邻近蛋白质组学和代谢示踪剂/脂质组学，结合强大的遗传模型以及内源性脂肪酸配体和化学探针的综合组，对脂肪细胞和肝细胞进行研究。我们的具体目标是：1）确定相互作用的分子基础。使用高分辨率荧光和透射电子对 ABHD5 与 WT PNPLA3 和 I148M 进行分析，以及脂肪细胞和肝细胞中 ABHD5 复合物的亚细胞定位和动态运输2) 使用无偏邻近蛋白质组学和定向免疫沉淀确定 ABHD5/PNPLA3 和 ABHD5/PNPLA3 I148M 代谢物的位置和配体依赖性蛋白质组成 3) 剖析 ABHD5/PNPLA3 和 ABHD5/PNPLA3 I148M 的代谢功能。使用功能获得和丧失遗传学研究脂肪细胞和肝细胞的代谢选择性内源性和合成的 ABHD5 配体与同位素示踪剂和脂质组学相结合，这些目标与 NIH 的使命完全一致，将在一个发现平台内实现，该平台最大限度地提高了分析水平（分子、细胞器、细胞和组织）的整合。）提供对 ABHD5/PNPLA3 功能的可靠分析，从而提高我们对脂质水平如何调节的理解，并确定肥胖相关疾病治疗干预的新点。